Novel Type 2 Diabetes Drugs Incur High Costs in Medicare Novel Type 2 Diabetes Drugs Incur High Costs in Medicare

In Medicare Part D, beneficiaries pay 3 to 8 times more out of pocket for SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors than for older glucose-lowering agents.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news